Gepants
Gepants are a class of small-molecule antagonists of the calcitonin gene-related peptide (CGRP) receptor. By blocking CGRP from binding to its receptor, gepants aim to inhibit a signaling pathway implicated in migraine pathophysiology. They are used for both acute treatment of migraine attacks and, for some agents, preventive therapy.
Representative gepants include ubrogepant and rimegepant, approved for acute treatment, and atogepant, approved for prevention. A
Gepants are non-vasoconstrictive, offering an alternative to triptans for patients with cardiovascular risk or who do
Common adverse events are generally mild and may include nausea, dry mouth, and dizziness. Hepatic safety concerns
Overall, gepants provide targeted CGRP-receptor antagonism with a distinct safety and administration profile compared with traditional